Florida is currently home to 3831 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Miami, Tampa, Jacksonville and Orlando. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
NCT04317534
Recruiting
A randomized trial of adjuvant Pembrolizumab following surgical resection versus observation following surgical resection in patients with stage I non-small cell lung cancer (NSCLC) with primary tumors between 1-4 cm. Patients will be randomized (1:1) 4-12 weeks following surgery to either: * Arm A: Pembrolizumab 400 mg every 6 weeks × 9 cycles * Arm B: Observation Stratification factors will include: PD-L1 TPS (\<50% vs. ≥50%), and tumor size (1-2 cm vs. \>2-4 cm)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/01/2025
Locations: Moffit Cancer Center, Tampa, Florida
Conditions: NSCLC, Stage I
Register for Updates
The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
NCT03509961
Recruiting
This study will evaluate the use of non- TBI (total body irradiation) conditioning for B-ALL patients with low risk of relapse as defined by absence of NGS-MRD (next generation sequencing minimal residual disease) before receiving a hematopoietic cell transplant (HCT). Patients diagnosed with B-ALL who are candidates for HCT will be screened by NGS-MRD on a test of bone marrow done before the HCT. Subjects who are pre-HCT NGS-MRD negative will be eligible to receive a non-TBI conditioning regime... Read More
Gender:
ALL
Ages:
Between 1 year and 25 years
Trial Updated:
05/01/2025
Locations: University of Florida, Gainesville, Florida
Conditions: B-cell Acute Lymphoblastic Leukemia
Register for Updates
An Investigational Study of ESK-001 in Participants With Normal Renal Function and Participants With Mild, Moderate, and Severe Impaired Renal Function
NCT06962774
Recruiting
This a phase 1, open label, single dose, parallel cohort study to determine the pharmacokinetics (PK) of study drug (ESK-001) in healthy volunteer participants, and participants with mild, moderate, and severe renal impairment.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/30/2025
Locations: Panax Clinical Research, Miami Lakes, Florida
Conditions: Renal Impairment
Register for Updates
A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants
NCT06720038
Recruiting
The objective of the study is to evaluate the safety, tolerability, and immunogenicity of 4 injections of VAX-31 (at 3 dose levels) compared to PCV20 in infants at 2, 4, 6, and 12-15 months of age, in addition to receiving routine US concomitant vaccines. Stage 1 of the study will comprise 3 dose ascending cohorts. Stage 2 of the study will enroll the remainder of the sample size.
Gender:
ALL
Ages:
Between 42 days and 89 days
Trial Updated:
04/30/2025
Locations: SEC Clinical Research, Pensacola, Florida
Conditions: Pneumococcal Vaccines
Register for Updates
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
NCT06233461
Recruiting
Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. The purpose of this study is to evaluate the efficacy and safety of TAK-279 versus placebo in participants with moderately to severely active Crohn's disease (CD). The main aim of this study is to learn if the 3 different doses of TAK-279 reduce bowel inflammation and ulcers in the bowel compared to the placebo after 12 weeks of treatment. Another aim is to compare any medical problems that... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/30/2025
Locations: West Central Gastroenterology, LLP, d/b/a/ Gastro Florida, Clearwater, Florida
Conditions: Crohn's Disease
Register for Updates
Treating Pulmonary Embolism With Laguna Thrombectomy System (TRUST)
NCT06041594
Recruiting
This is a prospective, multi-center, pivotal study to demonstrate the safety and effectiveness of the Laguna Thrombectomy System for the treatment of pulmonary embolism. The Laguna Thrombectomy System is an investigational device which consists of the Laguna Clot Retriever™ System and the Malibu Aspiration Catheter™ System. These devices are manufactured by Innova Vascular, Inc.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
04/30/2025
Locations: Manatee Memorial Hospital, Bradenton, Florida
Conditions: Pulmonary Embolism
Register for Updates
Intervening With Haitian Immigrants in the U.S. to Improve HIV Outcomes
NCT05947266
Recruiting
The goal of this clinical trial is to test a culturally tailored engagement and retention intervention for Haitian Immigrants Living With HIV (HILWH). The main questions it aims to answer are: * Does this intervention result in measurable engagement and retention in care? * Does this intervention result in measurable viral suppression within 6 months? Participants will * participate in a pilot health intervention entailing 4 individual meetings, approximately once monthly over a six-month per... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2025
Locations: Care Resource, Inc., Miami, Florida
Conditions: HIV Infection Primary
Register for Updates
Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers
NCT05395624
Recruiting
This is a Phase 1/2 study to evaluate the safety and tolerability of 18F-OP-801 in subjects with ALS, AD, MS, PD and age-matched HVs. 18F-OP-801 is intended as a biomarker for PET imaging of activated microglia and macrophages in regions of neuroinflammation.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/30/2025
Locations: Mayo Clinic Jacksonville, Jacksonville, Florida
Conditions: Amyotrophic Lateral Sclerosis (ALS), Parkinson Disease (PD), Alzheimer Disease (AD), Multiple Sclerosis (MS)
Register for Updates
Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer
NCT04929028
Recruiting
This phase II trial studies the side effects of chemotherapy and intensity modulated radiation therapy in treating patients with low-risk HIV-associated anal cancer, and nivolumab after standard of care chemotherapy and radiation therapy in treating patients with high-risk HIV-associated anal cancer. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Chemotherapy drugs, such as mitomycin, fluorouracil, and capecitabine, work in different ways to stop the growth of t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: AIDS-Related Anal Carcinoma, Anal Squamous Cell Carcinoma, HIV Infection, Rectal Squamous Cell Carcinoma, Stage III Anal Cancer AJCC v8, Anal Margin Squamous Cell Carcinoma, Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Anal Non-Keratinizing Squamous Cell Carcinoma, Stage IIB Anal Cancer AJCC v8
Register for Updates
Bupropion to Reduce Cancer Related Fatigue in Cancer Survivors
NCT03996265
Recruiting
This phase III trial studies how well bupropion works in reducing cancer related fatigue in cancer survivors. Cancer and its treatment can cause fatigue. Bupropion is a drug that is used to treat depression, as well as to help people quit smoking. It belongs to the family of drugs called antidepressants and works by increasing certain types of activity in the brain. Bupropion may reduce cancer-related fatigue by causing changes in inflammation and stress hormones.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2025
Locations: Holy Cross Hospital, Fort Lauderdale, Florida
Conditions: Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Register for Updates
An Investigational Study of ESK-001 in Participants With Normal Liver Function and Participants With Mild, Moderate, and Severe Liver Damage
NCT06952634
Recruiting
This a phase 1, open label, single dose, parallel cohort study to determine the pharmacokinetics (PK) of study drug (ESK-001) in healthy volunteer participants, and participants with mild, moderate, and severe hepatic impairment.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/29/2025
Locations: Panax Clinical Research, Miami Lakes, Florida
Conditions: Hepatic Impairment
Register for Updates
A Study to Investigate Safety, Tolerability and Pharmacokinetics of LAE102 in Postmenopausal Women
NCT06908707
Recruiting
The purpose of the study is to evaluate the safety, tolerability and pharmacokinetics (PK) of LAE102 in healthy postmenopausal women
Gender:
FEMALE
Ages:
Between 45 years and 75 years
Trial Updated:
04/29/2025
Locations: Fortrea Clinical Trials, Daytona Beach, Florida
Conditions: Postmenopausal, Healthy Adult Female Participants
Register for Updates